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AbstrAct
Hypertension is a global health issue of paramount importance, which has not spared the African continent 
where an unacceptably high prevalence of uncontrolled blood pressure prevails among its population. Renal 
denervation (RD) represents an invasive management option for resistant hypertension, acting via several different 
physiological pathways – mostly predicated on modification of the renal autonomic nervous system. The evidence 
base for RD has recently been expanded by three randomised, sham-controlled clinical trials, which demonstrated 
significant blood pressure reductions under a variety of clinical conditions. In this review, both the renal mechanisms 
underlying RD, as well as the clinical aspects of its application to hypertension, are discussed.
Keywords: renal denervation; hypertension.
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INtrODUctION
Hypertension control remains a pressing global health 
issue, and Africa is no exception in this regard. In a large 
South African survey (the South African National Health 
and Nutrition Examination Survey, SANHANES-1), the 
prevalence of hypertension was 35% in adults; it has 
been estimated that 9% of all deaths in South Africa can 
be attributed to the complications of hypertension [1,2]. 
Data from the same study recorded only 23% of hyper-
tensive patients as receiving antihypertensive therapy [2]. 
In a recent study of more than 10 000 individuals in sub-
Saharan Africa, the highest prevalence of uncontrolled 
hypertension (55.4% of women and 54.7% of men) was 
documented in South Africa (Soweto, an urban settle-
ment of more than 1.5 million people southwest of 
Johannesburg) [3]. The analysis of serum drug assays in 
100 hypertensive patients followed up at a South African 
tertiary referral centre revealed that 17% were non-
adherent to an angiotensin-converting enzyme inhibitor 
and 12% to a calcium channel blocker [4].
Renal denervation (RD) is an emerging therapy for 
resistant hypertension, predominantly acting via renal 
mechanisms to lower systemic blood pressure. Three 
recently published, randomised trials have provided 
robust evidence for the effectiveness of RD in treating 
hypertension [5-7]. An advantage of RD in comparison 
to pharmacotherapy is that its efficacy is independent of 
patient adherence. 
NEUrO-rENAL MEcHANIsMs OF rD
The afferent renal nerves, predominantly located in the 
renal pelvis, transmit impulses via the dorsal spinal cord 
to the central nervous system when activated by stretch 
forces (Figure 1) [8]. Higher centres to which these 
signals project include the nucleus tractus solitarius, 
paraventricular nucleus of the hypothalamus, rostral 
ventrolateral medulla, subfornical organ and the A5 
noradrenergic cell group [9-14] (Table 1). Renal afferent 
nerve activity stimulates the central nervous system to 
increase vasopressin and oxytocin release and leads to 
activation of efferent sympathetic neurons, which run 
to the kidneys. Efferent neurons course along para-
vertebral ganglia and large blood vessels to innervate 
organs located in the thoracolumbar region. In the heart, 
sympathetic nerves terminate in the sino-atrial node and 
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atrioventricular node, in addition to both ventricles. Car-
diac sympathetic stimulation increases chronotropy, dro-
motropy and inotropy, which cumulatively increase cardiac 
output and systolic blood pressure. Sympathetic nerves 
emanating from the central nervous system also pass 
through the stellate ganglia, which play an essential role in 
the development of tachyarrhythmias, such as ventricular 
tachycardia and atrial fibrillation [15]. 
In the lumbar region, efferent sympathetic nerves enter 
the kidneys via the renal arteries; after arborising alongside 
the renal artery branches, they course with the vasa 
vasorum and terminate in the efferent glomerular arteriole, 
the juxtaglomerular apparatus and renal tubules. Stimula-
tion of the juxtaglomerular apparatus causes renin release, 
which in turn activates the renin–angiotensin–aldosterone 
system (RAAS). The end products of RAAS activation, 
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Figure 1.  Neuro-renal axis and blood pressure regulation. complex connections between the central nervous system 
and kidney via the renal nerves include afferent signals, e.g., from renal chemoreceptors, and efferent signals, which regulate blood 
pressure via hypothalamic (e.g., vasopressin release) and renal (e.g., renin release) mechanisms. abbreviations: a5, noradrenergic 
cell group; c1R and c2R, renal chemoreceptors; DRG, dorsal root ganglion; Jc, juxtaglomerular cells; iMl, intermediolateral cell 
column; MR, renal mechanoreceptors; NtS, nucleus tractus solitarius; PvN, paraventricular nucleus of the hypothalamus; RvlM, 
rostral ventrolateral medulla; SFO, subfornical organ. Redrawn from Nishi et al. [8] with permission.
table 1.  central nervous system cell groups related to the 
neuro-renal axis.   
cell group
central 
neurotransmitter(s) 
with a postulated 
role in blood 
pressure control
Subfornical organ [9] • Serotonin
Paraventricular nucleus of the hypothalamus 
[10]
•  Gamma 
aminobutyric acid 
• Glutamate
A5 noradrenergic cell group [11] • Catecholamines
Rostral ventrolateral medulla [11-13]
• Catecholamines
•  Gamma 
aminobutyric acid 
• Glutamate 
• Glycine
Nucleus tractus solitarius (NTS) [14] • Adenosine
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angiotensin II (AT-II) and aldosterone, induce vasocon-
striction and renal tubular sodium and water retention, 
respectively. AT-II also exhibits a constrictor effect on 
the efferent glomerular arteriole, thereby raising intra-
glomerular pressure and filtration rate. Peripheral vascular 
resistance is also elevated by AT-II, which increases diastolic 
blood pressure, cardiac afterload and coronary perfusion. 
In the healthy kidney, stretching of the renal pelvis has an 
inhibitory effect on the efferent renal sympathetic nerves. 
In the hypo-perfused kidney, however, this inhibitory reflex 
is attenuated and results in sympatho-excitation, increased 
cardiac output, augmented glomerular filtration and sub-
sequent adrenal gland activation. Chronic and inappro-
priate activation of this system elevates systemic blood 
pressure. Although increased sympathetic tone is not the 
sole cause of primary hypertension, there is robust evi-
dence that the sympathetic nervous system plays a central 
role in the pathogenesis of hypertension [16]. The kidneys 
are therefore central to the pathogenesis of hypertension 
through autonomic regulation of increased peripheral 
resistance, sodium and water retention, as well as additional 
mechanisms [16]. Modification of the neuro-renal axis by 
disrupting the connection between the central nervous 
system and kidneys is an attractive therapeutic target, and 
both anatomical and physiological knowledge of the renal 
nerve supply support this approach [17,18].
In humans, non-selective surgical splanchnicectomy, which 
includes RD, was historically performed as a treatment for 
systemic hypertension [19] but abandoned due to unac-
ceptable side effects, including impotence, orthostatic 
hypotension and urinary incontinence. The advent of 
femoral endovascular access and therapies made non-
surgical RD a reality. Radiofrequency energy can be applied 
to the renal arteries through a dedicated helical catheter, 
causing thermal damage to the adventitial nerves (Figure 2). 
Heradien and co-workers recently reported on successful 
RD performed via brachial and radial artery punctures, 
which expands the options for vascular access to treat 
hypertension invasively [20]. Alternative vascular access 
routes for RD (such as via the radial artery) eliminate the 
risk of femoral access-related haemorrhage and allow 
patient discharge on the same day as the procedure. Non-
surgical RD, therefore, exerts its anti-hypertensive effects 
by inhibiting the neural traffic between the central nervous 
system and kidneys and has entered the clinical arena. 
cLINIcAL AsPEcts OF rD
The SYMPLICITY HTN-2 trial (Table 2) was the first 
randomised study to evaluate the clinical efficacy of RD 
after preclinical and proof-of-concept human studies [21]. 
In SYMPLICITY HTN-2, significant decreases (32 mmHg 
systolic and 12 mmHg diastolic) in blood pressure were 
seen in the RD group after 6 months, compared to those 
receiving drug therapy (P < 0.001) [21]. The much 
anticipated SYMPLICITY HTN-3 study (Table 2), however, 
could not demonstrate a significant difference in blood 
pressure reduction between RD treatment and a sham 
control group (P = 0.98) [22]. Numerous limitations of 
the SYMPLICITY HTN-3 trial have been identified since, 
e.g. modification of pharmacotherapy during the trial, a 
large range of operator experience in the RD procedure, 
proximal RD without the inclusion of more distal renal 
artery ablation and the fact that treatment adherence was 
not monitored objectively. The SPYRAL-HTN-OFF MED, 
SPYRAL-HTN-ON MED AND RADIANCE-HTN SOLO 
trials were designed to account for the limitations of the 
SYMPLICITY HTN-3 study (Table 2). Significant anti-
hypertensive effects of RD were seen in all three of these 
trials, which revived interest in RD, and substantially 
bolstered the evidence base for translating this modality 
into clinical practice. Very recently, the blood pressure 
lowering effect of RD was confirmed in a large, random-
ised, sham-controlled trial (SPYRAL HTN-OFF MED 
Pivotal) [23]. This international, multicentre trial recruited 
331 patients from 44 centres and demonstrated that 
RD with a quadripolar radiofrequency denervation catheter 
(Symplicity SpyralTM) signif icantly lowers ambulatory 
(-3.9 mmHg) and office blood pressure (-6.5 mmHg) to a 
greater degree than a sham procedure in hypertensive 
patients who did not take any blood pressure lowering 
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Figure 2.  Procedural aspects of renal denervation. 
a Symplicity SpyraltM (Medtronic, Galway, ireland) renal 
denervation catheter is advanced into the right main renal 
artery via a femoral puncture, whereafter radiofrequency 
energy is delivered to the peri-renal sympathetic nerves via 
the catheter. Reproduced with permission from Medtronic 
africa (Midrand, South africa).
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drugs. There were no major safety concerns noted during 
a 3-month follow-up period.
Whereas the abovementioned trials were randomised 
and sham-controlled, several randomised trials without a 
sham arm have been published (RADIOSOUND-HTN 
[24], RDN OSA [25], INSPiRED [26], SYMPATHY [27], 
DENERVHTA [28], PRAGUE-15 [29], DENER-HTN [30], 
SYMPLICITY HTN Japan [31] and RDN OSLO [32]). 
While some were in favour of RD, others were not. 
Registry data on RD have also been collected, e.g. in 
the Global Symplicity Registry [33], the UK Renal 
Denervation Affiliation study [34] and the Swedish National 
Registry [35].
In the SYMPLICITY HTN-3 trial, African-American patients 
experienced a greater blood pressure reduction in 
response to sham treatment than other demographic 
groups – a very intriguing signal which has been ascribed to 
a greater degree of drug therapy adherence but has not 
been fully explained [36]. The specific sub-groups of 
patients who will derive most benefit from RD, including 
demographic groups, is still largely unknown, and requires 
further study. The practice of RD on the African continent 
has not been systematically documented, nor has the 
efficacy of RD for hypertension been thoroughly studied 
in the African population. Patients in Africa with resistant 
hypertension have limited access to RD – as far as the 
authors are aware, only four private healthcare facilities in 
South Africa perform RD procedures regularly. A consensus 
statement on the appropriate use of RD was released by 
the South African Heart Association and Hypertension 
Society in 2013. This document proposes that RD be 
limited to registries or prospective studies, but it was 
compiled before the results of the SPYRAL-HTN-OFF 
MED, SPYRAL-HT-ON MED and RADIANCE-HTN 
SOLO trials were known. As the first step in RD rollout on 
the African continent and considering the constrained 
resources of many African healthcare systems, we propose 
the establishment of an African RD registry to assess 
treatment efficacy and safety in African patients.
Mechanisms and clinical use of renal denervation
table 2.  Randomised, sham-controlled trials of renal denervation.
Study Year published
No. of 
patients Objective Primary endpoint Outcome
RADIANCE-HTN SOLO [7] 2018 146
Comparison of ultrasound 
RD and sham groups for 
BP reduction without 
pharmacotherapy
Reduction in ambulatory 
systolic BP at 2 months 
post-randomisation
P = 0.0001 in favour of RD
SPYRAL HTN-ON MED [6] 2018 80
Comparison of 
radiofrequency RD 
(quadripolar catheter) 
and sham groups for BP 
reduction in patients with 
uncontrolled hypertension 
on pharmacotherapy
Reduction in ambulatory BP 
at 6 months
P = 0.0051 in favour of 
RD for systolic BP and P = 
0.0292 in favour of RD for 
diastolic BP
SPYRAL HTN-OFF MED [5] 2017 80
Comparison of 
radiofrequency RD 
(quadripolar catheter) 
and sham groups for 
BP reduction without 
pharmacotherapy
Reduction in ambulatory BP 
at 3 months
P = 0.0414 in favour of 
RD for systolic BP and P = 
0.0024 in favour of RD for 
diastolic BP
SYMPLICITY HTN-3 [22] 2014 535
Comparison of 
radiofrequency RD (single 
point catheter) and sham 
groups for BP reduction 
in patients with resistant 
hypertension
Reduction in office BP at 6 
months
P = 0.98 with no significant 
difference between RD and 
sham groups
SYMPLICITY HTN-2 [21] 2010 106
Comparison of 
radiofrequency RD (single 
point catheter) and sham 
groups for BP reduction 
in patients with resistant 
hypertension
Reduction in office BP at 6 
months
P < 0.0001 in favour of RD
Abbreviations: BP, blood pressure; RD, renal denervation.
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cONcLUsIONs
The kidney and its connections to the central nervous 
system are pivotal in the regulation of blood pressure and 
the pathogenesis of systemic hypertension. Disruption of 
this neuro-renal axis underlies therapeutic RD and is 
accomplished with trans-arterial access in the contem-
porary era. Recent trial evidence for the efficacy of RD in 
the treatment of hypertension has revitalised clinical 
interest. RD is still infrequently used in Africa but offers 
hope for mitigating the impact of the very considerable 
burden of uncontrolled hypertension.
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